Lyme	B-KP 0 4
disease	I-KP 5 12
can	O 13 16
be	O 17 19
classified	O 20 30
using	O 31 36
the	O 37 40
terminology	O 41 52
of	O 53 55
syphilis	B-KP 56 64
.	 O 64 65

In	O 66 68
this	O 69 73
series	O 74 80
of	O 81 83
95	O 84 86
cases	O 87 92
from	O 93 97
the	O 98 101
upper	O 102 107
midwest	O 108 115
,	 O 115 116
early	O 117 122
cases	O 123 128
,	 O 128 129
defined	O 130 137
as	O 138 140
an	O 141 143
illness	O 144 151
of	O 152 154
<2	O 155 157
months	O 158 164
,	 O 164 165
were	O 166 170
more	O 171 175
likely	O 176 182
to	O 183 185
have	O 186 190
lived	O 191 196
in	O 197 199
or	O 200 202
recently	O 203 211
visited	O 212 219
a	O 220 221
highly	O 222 228
endemic	B-KP 229 236
area	I-KP 237 241
.	 O 241 242

Unlike	O 243 249
late	O 250 254
cases	O 255 260
,	 O 260 261
early	O 262 267
cases	O 268 273
presented	O 274 283
entirely	O 284 292
in	O 293 295
the	O 296 299
nonwinter	O 300 309
months	O 310 316
(	 O 317 318
p	O 318 319
<	O 320 321
.	 O 322 323
001	O 323 326
)	 O 326 327
.	 O 327 328

Early	O 329 334
disease	O 335 342
was	O 343 346
further	O 347 354
subdivided	O 355 365
into	O 366 370
primary	O 371 378
and	O 379 382
secondary	O 383 392
disease	O 393 400
.	 O 400 401

Ninety	O 402 408
percent	O 409 416
of	O 417 419
primary	O 420 427
and	O 428 431
43	O 432 434
%	 O 434 435
of	O 436 438
secondary	O 439 448
cases	O 449 454
had	O 455 458
erythema	B-KP 459 467
migrans	I-KP 468 475
,	 O 475 476
while	O 477 482
no	O 483 485
late	O 486 490
cases	O 491 496
had	O 497 500
active	O 501 507
erythema	B-KP 508 516
migrans	I-KP 517 524
(	 O 525 526
p	O 526 527
<	O 528 529
.	 O 530 531
001	O 531 534
)	 O 534 535
.	 O 535 536

Clinical	B-KP 537 545
manifestations	I-KP 546 560
of	I-KP 561 563
nonspecific	I-KP 564 575
inflammation	I-KP 576 588
,	 O 588 589
except	O 590 596
for	O 597 600
arthralgia	B-KP 601 611
,	 O 611 612
were	O 613 617
more	O 618 622
common	O 623 629
in	O 630 632
early	O 633 638
than	O 639 643
late	O 644 648
disease	O 649 656
(	 O 657 658
p	O 658 659
<	O 660 661
.	 O 662 663
01	O 663 665
)	 O 665 666
.	 O 666 667

In	O 668 670
secondary	O 671 680
cases	O 681 686
,	 O 686 687
monoarticular	B-KP 688 701
arthritis	I-KP 702 711
was	O 712 715
slightly	O 716 724
more	O 725 729
common	O 730 736
than	O 737 741
polyarticular	B-KP 742 755
arthritis	I-KP 756 765
,	 O 765 766
with	O 767 771
the	O 772 775
reverse	O 776 783
occurring	O 784 793
in	O 794 796
late	O 797 801
disease	O 802 809
(	 O 810 811
p	O 811 812
<	O 813 814
.	 O 815 816
05	O 816 818
)	 O 818 819
.	 O 819 820

Indirect	B-KP 821 829
fluorescent	I-KP 830 841
antibody	I-KP 842 850
testing	I-KP 851 858
revealed	O 859 867
a	O 868 869
ratio	O 870 875
of	O 876 878
IgM	B-KP 879 882
to	O 883 885
IgG	B-KP 886 889
antibodies	I-KP 890 900
to	O 901 903
be	O 904 906
helpful	O 907 914
in	O 915 917
distinguishing	O 918 932
early	O 933 938
from	O 939 943
late	O 944 948
disease	O 949 956
.	 O 956 957

Antibacterial	B-KP 958 971
therapy	I-KP 972 979
in	O 980 982
early	O 983 988
,	 O 988 989
primary	O 990 997
cases	O 998 1003
caused	O 1004 1010
Jarisch-Herxheimer	B-KP 1011 1029
reaction	O 1030 1038
7	O 1039 1040
%	 O 1040 1041
of	O 1042 1044
the	O 1045 1048
time	O 1049 1053
.	 O 1053 1054

Despite	O 1055 1062
longer	O 1063 1069
and	O 1070 1073
more	O 1074 1078
frequent	O 1079 1087
parenteral	O 1088 1098
therapy	O 1099 1106
,	 O 1106 1107
late	O 1108 1112
Lyme	B-KP 1113 1117
disease	I-KP 1118 1125
frequently	O 1126 1136
required	O 1137 1145
retreatment	O 1146 1157
,	 O 1157 1158
owing	O 1159 1164
to	O 1165 1167
poor	O 1168 1172
clinical	O 1173 1181
response	O 1182 1190
(	 O 1191 1192
p	O 1192 1193
<	O 1194 1195
.	 O 1196 1197
05	O 1197 1199
)	 O 1199 1200
.	 O 1200 1201

